Nicotinic acid: An unjustly neglected remedy;Kyselina nikotinová: Lék neprávem opomí jený

Casopis Lekaru Ceskych

Volumn 145, Issue 11, 2006, Pages 825-831

  Žák, Aleš ^a,b   Zeman, M ^a   Vecka, M ^a   Tvrzicka E ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b NONE   (Czech Republic)

Author keywords

Changes in cardiovascular morbidity and mortality; Deterioration of glucose homeostasis; Flush; Hepatotoxicity; Hypolipidemic effects; Inhibition of lipolysis; Niacin; Sustained (extended resp.) release

Indexed keywords

ACETYLSALICYLIC ACID; CYCLOSPORIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INDOBUFEN; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PREDNISONE; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN; ANTILIPEMIC AGENT;

ADIPOSE TISSUE; ANTICOAGULATION; ANTIOXIDANT ACTIVITY; CARDIOVASCULAR DISEASE; CHOLESTEROL TRANSPORT; CLINICAL PRACTICE; CLINICAL TRIAL; CZECH REPUBLIC; DOSE RESPONSE; DRUG MECHANISM; DRUG STRUCTURE; DYSLIPIDEMIA; EVIDENCE BASED MEDICINE; FLUSHING; GLUCOSE HOMEOSTASIS; HUMAN; LIPOLYSIS; LIVER TOXICITY; METABOLIC SYNDROME X; MORBIDITY; MORTALITY; PELLAGRA; RECEPTOR UPREGULATION; REVIEW; SIDE EFFECT; SUSTAINED RELEASE PREPARATION; HYPERLIPIDEMIA;

ANTILIPEMIC AGENTS; HUMANS; HYPERLIPIDEMIAS; NIACIN;

EID: 33750943192     PISSN: 00087335     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (25)

1. Bender, D. A.: Nutritional Biochemistry of the vitamins. 2. vyd. Cambridge, Cambridge University Press, 2003, 488 s.
2. Ganji, S. H., Kamanna, V. S., Kashyap, M. L.: Niacin and cholesterol: role in cardiovascular disease (Review). J. Nutr. Biochem., 2003, 14, s. 298-305.
3. Meyers, C. D., Kamanna, V. S., Kashyap, M. L.: Niacin therapy in atherosclerosis. Curr. Opin. Lipidol., 2004, 15, s. 659-665.
4. Altschul, R., Hoffer, A., Stehen, J. D.: Influence of nicotinic acid on serum cholesterol in man. Arch. Biochem. Biophys., 1955, 54, s. 558-559.
5. th anniversary review. J. Intern. Med., 2005, 258, s. 94-114.
6. Guyton, Jr., Giotto Jr., A. M.: Drug Therapy of dyslipoproteinemias. In: Fruchart, J. C., Shepherd, J. (Eds): Human Plasma of Lipoproteins. New York, Walter de Gruyter, 1989, s. 335-361.
7. Talbert, R. L.: Current recommendation for the treatment of dyslipidemia. Continuing Education Credits. P. T., 2004, 29, s. 104-112.
8. McCarty, M. F.: Co-administration of equimolar doses of betaine may alleviate the hepatotoxicity risk associated with niacin therapy. Med. Hypotheses, 2000, 55, s. 189-194.
9. Gotto, A. M., Pownall, H.: Manual of Lipid Disorders. 3. vyd. Philadelphia, Lippincott Williams & Wilkins, 2003.
10. Carlson, L. A., Oro, L.: Persistence of inhibitory effect of nicotinic acid on catecholamin stimulated lipid mobilization during prolonged treatment with nicotinic acid. J. Atheroscl. Res., 1965, 5, s. 436-439.
11. Westphal, S., Borucki, K., Taneva, E. et al.: Extended-release niacin raises adiponectin and leptin. Atherosclerosis, 2006. Epub ahead of print.
12. Desouza, C., Keebler, M., McNamara, D. B. et al.: Drug affecting homocystein metabolism: impact on cardiovascular risk. Drugs, 2002, 62, s. 605-616.
13. Toth, P. P.: High-density lipoprotein as a therapeutic target: Clinical evidence and treatment strategies. Am. J. Cardiol., 2005, 96 (Suppl. 9A), s. 50K-58K.
14. Robinson, A. W., Sloan, H. L., Arnold, G.: Use of Niacin in the prevention and management of hyperlipidemia. Prog. Cardiovasc. Nurs., 2002, 16, s. 14-20.
15. Grundy, S. M., Mok, H. Y. I., Zech, L. et al.: Influence of nicotinic acid on metabolism of cholesterol and triglycerides in men. J. Lipid Res., 1981, 22, s. 24-36.
16. The Coronary Drag Project Research Group.: The Coronary Drug Project. Design, Methods, and Baseline Results. Circulation, 1973, 47 (Suppl.), s. I6-I29.
17. Carlson, R. A., Rosenhamer, G.: Reduction of mortality in the Stockholm Ischemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med. Scand., 1988, 223, s. 405-418.
18. The Coronary Drug Project Research Group.: Clofibrate and niacin in coronary heart disease. JAMA, 1975, 231, s. 360-381.
19. Studer, M., Briel, M., Leimenstoll, B. et al.: Effect of different antilipidemic agents and diets on mortality. Arch. Intern. Med., 2005, 165, s. 725-730.
20. Cashin Hemphill, L., Mack, W. J., Pogoda, J. M. et al.: Beneficial effects of colestipol-niacin on coronary atherosclerosis: a 4-year folow-up study. JAMA, 1990, 264, s. 3013-3017.
21. Brown, G., Labers, J. J., Fischer, L. D. et al.: Régression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. New Engl. J. Med., 1990, 323, s. 1289-1298.
22. Brown, B. G., Zhao, X. Q., Chait, A. et al.: Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary heart disease. N. Engl. J. Med., 2001, 345, s. 1583-1592.
23. Elam, M. B., Hunnikhage, D. B., Davis, K. B. et al.: Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: A randomized trial. Arterial Disease Multiply Intervention Trial. JAMA, 2000, 284, s. 1263-1270.
24. Taylor, A. J., Sullenberger, L. E., Lee, H. J. et al.: Arterial biology for the investigation of the treatment effects of reducing cholesterol (ARBITER) 2. A double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation, 2004, 110, s. 3512-3517.
25. Zema, M. J.: Gemifibrozil, nicotinic acid combination therapy in patients with isolated hypoalphalipoproteinemia: a randomized, open-label, crossover study. J. Am. Coll. Cardiol., 2000, 35, s. 640-646.